Efficacy of switching to entecavir monotherapy in Japanese lamivudine‐pretreated patients

摘要: Background and Aims:  To assess the efficacy of switching Japanese chronic hepatitis B patients from lamivudine monotherapy to entecavir 0.5 mg/day. Methods:  A retrospective analysis was conducted on 134 switched between September 2006 February 2008 for 6 months or more. Patients were divided into three groups based viral load at point (baseline  5.0 log10 copies/mL). Results:  At baseline, detection lamivudine-resistant virus highest in with higher (HBV) DNA (76% vs 23% ≥ 2.6  3 years, 1–3 years < 1 year, respectively). Two years after switching, HBV suppression less than 2.6 log10 copies/mL achieved 100% (32/32), 92% (12/13) 44% (4/9) 2.6, 2.6–5.0 more 5.0 log10 baseline groups, respectively. Alanine aminotransferase (ALT) normalization occurred 76–96% 90–100% following 1 2 years treatment, One patient (2.6–5.0 log10 copies/mL) mutants developed resistance week 48 during follow up. Conclusion:  Switching 0.5 mg/day achieves maintains undetectable levels ALT over 2 years, especially copies/mL.